Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewSIB 1757
Discontinued Product
1215 has been discontinued.
View all Glutamate (Metabotropic) Group I Receptors products.
说明： Highly selective mGlu5 antagonist
化学名： 6-Methyl-2-(phenylazo)-3-pyridinol
生物活性 for SIB 1757
SIB 1757 is a highly selective antagonist for the mGlu5 metabotropic glutamate receptor subtype; displays an IC50 value of 0.4 μM at hmGlu5 compared with > 30 μM at hmGlu1b, hmGlu2, hmGlu4, hmGlu6, hmGlu7 and hmGlu8.
技术数据 for SIB 1757
| 分子量 | 213.24 |
| 公式 | C12H11N3O |
| 储存 | Store at RT |
| CAS Number | 31993-01-8 |
| PubChem ID | 5311432 |
| InChI Key | SISOFUCTXZKSOQ-ZHACJKMWSA-N |
| Smiles | CC1=NC(\N=N\C2=CC=CC=C2)=C(O)C=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for SIB 1757
参考文献 for SIB 1757
参考文献是支持产品生物活性的出版物。
Varney et al (1999) SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J.Pharmacol.Exp.Ther. 290 170 PMID: 10381773
Varney et al (1999) Characterisation of SIB-1757 and SIB-1893: highly selective antagonists at metabotropic glutamate receptor subtype 5. Br.J.Pharmacol. 126 248P
关键词: SIB 1757, SIB 1757 supplier, selective, mGlu5, mGluR5, antagonist, Group, I, Receptors, Glutamate, Metabotropic, SIB1757, (Metabotropic), 1215, Tocris Bioscience
3 篇 SIB 1757 的引用文献
引用文献是使用了 Tocris 产品的出版物。 SIB 1757 的部分引用包括：
Zhao et al (2018) Soluble Aβ Oligomers Impair Dipolar Heterodendritic Plasticity by Activation of mGluR in the Hippocampal CA1 Region. iScience 6 138 PMID: 30240608
Koeglsperger et al (2013) Impaired glutamate recycling and GluN2B-mediated neuronal calcium overload in mice lacking TGF-β1 in the CNS. Glia 61 985 PMID: 23536313
El-Kouhen et al (2006) Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist. Br J Pharmacol 149 761 PMID: 17016515
SIB 1757 的评论
目前没有该产品的评论。 Be the first to review SIB 1757 and earn rewards!
Have you used SIB 1757?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.